Steven Gillis - Net Worth and Insider Trading

Steven Gillis Net Worth

The estimated net worth of Steven Gillis is at least $73,837 dollars as of 2024-12-26. Steven Gillis is the Director of Pulmatrix Inc and owns about 11,432 shares of Pulmatrix Inc (PULM) stock worth over $69,308. Steven Gillis is the Director of Codiak BioSciences Inc and owns about 2,503,903 shares of Codiak BioSciences Inc (CDAKQ) stock worth over $4,006. Steven Gillis is also the Director of VBI Vaccines Inc and owns about 1,046,106 shares of VBI Vaccines Inc (VBIVQ) stock worth over $523. Details can be seen in Steven Gillis's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Steven Gillis has not made any transactions after 2023-07-10 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Steven Gillis

Steven Gillis Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Steven Gillis owns 13 companies in total, including Codiak BioSciences Inc (CDAKQ) , Pulmatrix Inc (PULM) , and Homology Medicines Inc (FIXX) among others .

Click here to see the complete history of Steven Gillis’s form 4 insider trades.

Insider Ownership Summary of Steven Gillis

Ticker	Comapny	Transaction Date	Type of Owner
CDAKQ	Codiak BioSciences Inc	2020-10-16	director
PULM	Pulmatrix Inc	2016-02-03	director
FIXX	Homology Medicines Inc	2018-03-27	director
		2023-07-10	director
		2019-02-22	10 percent owner
		2017-05-25	director & 10 percent owner
		2014-01-23	director
		2021-07-15	10 percent owner
		2021-02-03	10 percent owner
		2021-06-16	10 percent owner
		2021-07-27	10 percent owner
		2022-10-19	10 percent owner
		2023-09-14	10 percent owner

Steven Gillis Latest Holdings Summary

Steven Gillis currently owns a total of 3 stocks. Among these stocks, Steven Gillis owns 11,432 shares of Pulmatrix Inc (PULM) as of June 16, 2015, with a value of $69,308 and a weighting of 93.87%. Steven Gillis owns 2,503,903 shares of Codiak BioSciences Inc (CDAKQ) as of October 16, 2020, with a value of $4,006 and a weighting of 5.43%. Steven Gillis also owns 1,046,106 shares of VBI Vaccines Inc (VBIVQ) as of July 10, 2023, with a value of $523 and a weighting of 0.71%.

Latest Holdings of Steven Gillis

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
PULM	Pulmatrix Inc	2015-06-16	11,432	6.06	69,308
CDAKQ	Codiak BioSciences Inc	2020-10-16	2,503,903	0.00	4,006
VBIVQ	VBI Vaccines Inc	2023-07-10	1,046,106	0.00	523

Holding Weightings of Steven Gillis

Steven Gillis Form 4 Trading Tracker

According to the SEC Form 4 filings, Steven Gillis has made a total of 0 transactions in Pulmatrix Inc (PULM) over the past 5 years. The most-recent trade in Pulmatrix Inc is the acquisition of 364 shares on June 16, 2015, which cost Steven Gillis around $500,520.

According to the SEC Form 4 filings, Steven Gillis has made a total of 1 transactions in Codiak BioSciences Inc (CDAKQ) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Codiak BioSciences Inc is the acquisition of 235,000 shares on October 16, 2020, which cost Steven Gillis around $4 Million.

According to the SEC Form 4 filings, Steven Gillis has made a total of 1 transactions in VBI Vaccines Inc (VBIVQ) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in VBI Vaccines Inc is the acquisition of 609,090 shares on July 10, 2023, which cost Steven Gillis around $1 Million.

Insider Trading History of Steven Gillis

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Steven Gillis Trading Performance

GuruFocus tracks the stock performance after each of Steven Gillis's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Steven Gillis is 24.99%. GuruFocus also compares Steven Gillis's trading performance to market benchmark return within the same time period. The performance of stocks bought by Steven Gillis within 3 months outperforms 3 times out of 5 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Steven Gillis's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Steven Gillis

Average Return

Average return per transaction

Outperforming Transactions

2 out of 5 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-3.72
Relative Return to S&P 500(%)	-5.52

Steven Gillis Ownership Network

Ownership Network List of Steven Gillis

No Data

Ownership Network Relation of Steven Gillis

Steven Gillis Owned Company Details

What does Codiak BioSciences Inc do?

Who are the key executives at Codiak BioSciences Inc?

Steven Gillis is the director of Codiak BioSciences Inc. Other key executives at Codiak BioSciences Inc include See Remarks Yalonda Howze , Chief Scientific Officer Sriram Sathyanarayanan , and See Remarks Nicole Barna .

Codiak BioSciences Inc (CDAKQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Codiak BioSciences Inc (CDAKQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Codiak BioSciences Inc (CDAKQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Codiak BioSciences Inc (CDAKQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Codiak BioSciences Inc Insider Transactions

No Available Data

What does Pulmatrix Inc do?

Who are the key executives at Pulmatrix Inc?

Steven Gillis is the director of Pulmatrix Inc. Other key executives at Pulmatrix Inc include Interim CFO Peter Ludlum , Chief Medical Officer Margaret Wasilewski , and Vice President & Finance Michelle Siegert .

Pulmatrix Inc (PULM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Pulmatrix Inc (PULM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Pulmatrix Inc (PULM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Pulmatrix Inc (PULM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Pulmatrix Inc Insider Transactions

No Available Data

What does Homology Medicines Inc do?

Who are the key executives at Homology Medicines Inc?

Steven Gillis is the director of Homology Medicines Inc. Other key executives at Homology Medicines Inc include director & President & CEO Arthur Tzianabos , See Remarks Paul Alloway , and Chief Scientific Officer Albert Seymour .

Homology Medicines Inc (FIXX) Insider Trades Summary

Over the past 18 months, Steven Gillis made no insider transaction in Homology Medicines Inc (FIXX). Other recent insider transactions involving Homology Medicines Inc (FIXX) include a net sale of 1,952 shares made by Julie Jordan , a net sale of 13,037 shares made by Arthur Tzianabos , and a net sale of 7,280 shares made by Paul Alloway .

In summary, during the past 3 months, insiders sold 0 shares of Homology Medicines Inc (FIXX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,413 shares of Homology Medicines Inc (FIXX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,413 shares.

Homology Medicines Inc (FIXX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Homology Medicines Inc Insider Transactions

No Available Data

What does VBI Vaccines Inc do?

Who are the key executives at VBI Vaccines Inc?

Steven Gillis is the director of VBI Vaccines Inc. Other key executives at VBI Vaccines Inc include 10 percent owner Perceptive Life Sciences Master Fund Ltd , Chief Commercial Officer John Robert Dillman , and Director & Corp Development/IR Nell Beattie .

VBI Vaccines Inc (VBIVQ) Insider Trades Summary

Over the past 18 months, Steven Gillis made 1 insider transaction in VBI Vaccines Inc (VBIVQ) with a net purchase of 609,090.

In summary, during the past 3 months, insiders sold 0 shares of VBI Vaccines Inc (VBIVQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of VBI Vaccines Inc (VBIVQ) were sold and 609,090 shares were bought by its insiders, resulting in a net purchase of 609,090 shares.

VBI Vaccines Inc (VBIVQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

VBI Vaccines Inc Insider Transactions

No Available Data

What does Sienna Biopharmaceuticals Inc do?

Who are the key executives at Sienna Biopharmaceuticals Inc?

Steven Gillis is the 10 percent owner of Sienna Biopharmaceuticals Inc. Other key executives at Sienna Biopharmaceuticals Inc include Chief Financial Officer Alexander Azoy , Chief Medical Officer Paul F. Lizzul , and director & President & CEO Iii Frederick Beddingfield .

Sienna Biopharmaceuticals Inc (SNNAQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sienna Biopharmaceuticals Inc (SNNAQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sienna Biopharmaceuticals Inc (SNNAQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sienna Biopharmaceuticals Inc (SNNAQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sienna Biopharmaceuticals Inc Insider Transactions

No Available Data

What does PhaseRx Inc do?

Who are the key executives at PhaseRx Inc?

Steven Gillis is the director & 10 percent owner of PhaseRx Inc. Other key executives at PhaseRx Inc include Chief Medical Officer Gordon Brandt , director & 10 percent owner Brian G Atwood , and 10 percent owner Robert Nelsen .

PhaseRx Inc (PZRXQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of PhaseRx Inc (PZRXQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of PhaseRx Inc (PZRXQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

PhaseRx Inc (PZRXQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

PhaseRx Inc Insider Transactions

No Available Data

What does bluebird bio Inc do?

Who are the key executives at bluebird bio Inc?

Steven Gillis is the director of bluebird bio Inc. Other key executives at bluebird bio Inc include Chief Medical Officer Richard A Colvin , President of SGD Andrew Obenshain , and Chief Commercial Officer & SGD Thomas J Klima .

bluebird bio Inc (BLUE) Insider Trades Summary

Over the past 18 months, Steven Gillis made no insider transaction in bluebird bio Inc (BLUE). Other recent insider transactions involving bluebird bio Inc (BLUE) include a net sale of 29,843 shares made by Andrew Obenshain , a net sale of 12,534 shares made by Richard A Colvin , and a net sale of 12,043 shares made by Thomas J Klima .

In summary, during the past 3 months, insiders sold 190 shares of bluebird bio Inc (BLUE) in total and bought 0 shares, with a net sale of 190 shares. During the past 18 months, 3,208 shares of bluebird bio Inc (BLUE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 3,208 shares.

bluebird bio Inc (BLUE)'s detailed insider trading history can be found in Insider Trading Tracker table.

bluebird bio Inc Insider Transactions

No Available Data

What does Erasca Inc do?

Who are the key executives at Erasca Inc?

Steven Gillis is the 10 percent owner of Erasca Inc. Other key executives at Erasca Inc include director & 10 percent owner & See Remarks Jonathan E Lim , Chief Medical Officer Shannon Morris , and General Counsel Ebun Garner .

Erasca Inc (ERAS) Insider Trades Summary

Over the past 18 months, Steven Gillis made no insider transaction in Erasca Inc (ERAS). Other recent insider transactions involving Erasca Inc (ERAS) include a net purchase of 2,000,000 shares made by Jonathan E Lim , a net purchase of 110,000 shares made by Alexander W. Casdin , and a net purchase of 10,000 shares made by Start Valerie Denise Harding .

In summary, during the past 3 months, insiders sold 0 shares of Erasca Inc (ERAS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Erasca Inc (ERAS) were sold and 2,120,000 shares were bought by its insiders, resulting in a net purchase of 2,120,000 shares.

Erasca Inc (ERAS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Erasca Inc Insider Transactions

No Available Data

What does Sana Biotechnology Inc do?

Who are the key executives at Sana Biotechnology Inc?

Steven Gillis is the 10 percent owner of Sana Biotechnology Inc. Other key executives at Sana Biotechnology Inc include director & Head of SanaX Richard Mulligan , 10 percent owner Keith Crandell , and 10 percent owner Arch Venture Fund X Overage, L.p. .

Sana Biotechnology Inc (SANA) Insider Trades Summary

Over the past 18 months, Steven Gillis made no insider transaction in Sana Biotechnology Inc (SANA). Other recent insider transactions involving Sana Biotechnology Inc (SANA) include a net purchase of 1,818,181 shares made by Arch Venture Fund X Overage, L.p. , a net purchase of 1,818,181 shares made by Keith Crandell , and a net purchase of 1,818,181 shares made by Robert Nelsen .

In summary, during the past 3 months, insiders sold 0 shares of Sana Biotechnology Inc (SANA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 400,000 shares of Sana Biotechnology Inc (SANA) were sold and 5,454,543 shares were bought by its insiders, resulting in a net purchase of 5,054,543 shares.

Sana Biotechnology Inc (SANA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sana Biotechnology Inc Insider Transactions

No Available Data

What does Verve Therapeutics Inc do?

Who are the key executives at Verve Therapeutics Inc?

Steven Gillis is the 10 percent owner of Verve Therapeutics Inc. Other key executives at Verve Therapeutics Inc include Chief Financial Officer Allison Dorval , See Remarks Andrew D. Ashe , and Chief Administrative Officer Joan Nickerson .

Verve Therapeutics Inc (VERV) Insider Trades Summary

Over the past 18 months, Steven Gillis made no insider transaction in Verve Therapeutics Inc (VERV). Other recent insider transactions involving Verve Therapeutics Inc (VERV) include a net sale of 1,109 shares made by Allison Dorval , a net purchase of 1,800,000 shares made by Krishna Yeshwant , and a net purchase of 76,000 shares made by Andrew D. Ashe .

In summary, during the past 3 months, insiders sold 555 shares of Verve Therapeutics Inc (VERV) in total and bought 0 shares, with a net sale of 555 shares. During the past 18 months, 2,623 shares of Verve Therapeutics Inc (VERV) were sold and 1,876,000 shares were bought by its insiders, resulting in a net purchase of 1,873,377 shares.

Verve Therapeutics Inc (VERV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Verve Therapeutics Inc Insider Transactions

No Available Data

What does DA32 Life Science Tech Acquisition Corp do?

Who are the key executives at DA32 Life Science Tech Acquisition Corp?

Steven Gillis is the 10 percent owner of DA32 Life Science Tech Acquisition Corp. Other key executives at DA32 Life Science Tech Acquisition Corp include director & 10 percent owner Keith Crandell , director & 10 percent owner & other: Director by deputization Deerfield Management Company, L.p. (series C) , and 10 percent owner & other: Director by Deputization Section 32 Fund 3, Lp .

DA32 Life Science Tech Acquisition Corp (DALS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of DA32 Life Science Tech Acquisition Corp (DALS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of DA32 Life Science Tech Acquisition Corp (DALS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

DA32 Life Science Tech Acquisition Corp (DALS)'s detailed insider trading history can be found in Insider Trading Tracker table.

DA32 Life Science Tech Acquisition Corp Insider Transactions

No Available Data

What does Prime Medicine Inc do?

Who are the key executives at Prime Medicine Inc?

Steven Gillis is the 10 percent owner of Prime Medicine Inc. Other key executives at Prime Medicine Inc include director & 10 percent owner Robert Nelsen , 10 percent owner Arch Venture Partners X, Llc , and 10 percent owner Gv 2019 Gp, L.l.c. .

Prime Medicine Inc (PRME) Insider Trades Summary

Over the past 18 months, Steven Gillis made no insider transaction in Prime Medicine Inc (PRME). Other recent insider transactions involving Prime Medicine Inc (PRME) include a net purchase of 3,200,000 shares made by Arch Venture Partners X, Llc , a net purchase of 3,200,000 shares made by Arch Venture Partners Xii, Llc , and a net purchase of 3,200,000 shares made by Robert Nelsen .

In summary, during the past 3 months, insiders sold 0 shares of Prime Medicine Inc (PRME) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Prime Medicine Inc (PRME) were sold and 9,600,000 shares were bought by its insiders, resulting in a net purchase of 9,600,000 shares.

Prime Medicine Inc (PRME)'s detailed insider trading history can be found in Insider Trading Tracker table.

Prime Medicine Inc Insider Transactions

No Available Data

What does Neumora Therapeutics Inc do?

Who are the key executives at Neumora Therapeutics Inc?

Steven Gillis is the 10 percent owner of Neumora Therapeutics Inc. Other key executives at Neumora Therapeutics Inc include Head of R&D Robert A. Lenz , Chief Financial Officer Joshua Pinto , and 10 percent owner Arch Venture Partners Xii, Llc .

Neumora Therapeutics Inc (NMRA) Insider Trades Summary

Over the past 18 months, Steven Gillis made no insider transaction in Neumora Therapeutics Inc (NMRA). Other recent insider transactions involving Neumora Therapeutics Inc (NMRA) include a net purchase of 2,007,064 shares made by Kristina Burow , a net purchase of 507,064 shares made by Arch Venture Partners Xii, Llc , and a net sale of 88,235 shares made by Robert A. Lenz .

In summary, during the past 3 months, insiders sold 35,611 shares of Neumora Therapeutics Inc (NMRA) in total and bought 0 shares, with a net sale of 35,611 shares. During the past 18 months, 210,023 shares of Neumora Therapeutics Inc (NMRA) were sold and 7,293,833 shares were bought by its insiders, resulting in a net purchase of 7,083,810 shares.

Neumora Therapeutics Inc (NMRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Neumora Therapeutics Inc Insider Transactions

No Available Data

Steven Gillis Mailing Address

Above is the net worth, insider trading, and ownership report for Steven Gillis. You might contact Steven Gillis via mailing address: 8755 W. Higgins Road, Suite 1025, Chicago Il 60631.

Discussions on Steven Gillis

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.